Only minimally SBIR involved and that some time ago, Immunome Inc (NASDAQ:IMNM) has nonetheless been in receipt of substantial other federal funding. A biotechnology company with a growing pipeline of cancer immunotherapies produced by a unique and powerful immunotherapy discovery engine, Immunome's proprietary RealMAb⢠technology enables the simultaneous discovery of novel antigens and the cognate native human antibodies that target those antigens. Originally developed at Massachusetts Institute of Technology's Whitehead Institute, RealMAb utilizes the human immune system response to circumvent the weaknesses, complications and inefficiencies of non-human approaches. After identification, Immunome employs its proprietary screening technology to screen for functional and specific cancer activity of these antigen antibody pairs.
